Albemarle vs DuPont de Nemours
ALB and DD side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALB and DD compare
DuPont de Nemours is the larger company, worth 1.8 times as much as Albemarle ($19.0B against $10.7B).
On earnings, DuPont de Nemours is cheaper: it trades at 312× trailing earnings, against 337× for Albemarle.
Albemarle grew revenue faster over the last twelve months (18.3% versus 3.3% for DuPont de Nemours).
Albemarle keeps more of each dollar of sales as profit, with a net margin of 3.8% compared with 0.79% at DuPont de Nemours.
Both pay dividends: Albemarle yields 1.8% and DuPont de Nemours 1.7%.
Albemarle scores higher on the StockData Score (16 against 10 for DuPont de Nemours), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALB | DD |
|---|---|---|
| Size and price | ||
| Market cap | $10.7B | $19.0B |
| Share price | $91.00 | $140.58 |
| Change, 1 year | −7.0% | −42.8% |
| Change, 5 years | −66.6% | −41.7% |
| Beta (5Y) | 1.68 | 1.16 |
| Employees | 7,800 | 15K |
| StockData Score | ||
| Total score | 16 (better) | 10 |
| Valuation score | 4 (better) | 1 |
| Growth score | 3 | 3 |
| Performance score | 1 (better) | 0 |
| Health score | 4 | 4 |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | 337× | 312× (better) |
| P/S | 1.8× (better) | 2.7× |
| P/B | 1.0× (better) | 1.4× |
| EV/EBITDA | 12.6× (better) | 22.4× |
| P/FCF | 8.0× (better) | 27.0× |
| FCF yield | 12.5% (better) | 3.7% |
| Fair value | $117.07 | $95.49 |
| Margin of safety | 22.3% (better) | −47.2% |
| Growth | ||
| Revenue growth (TTM) | 18.3% (better) | 3.3% |
| Revenue growth, 5Y average | 10.4% (better) | −9.3% |
| Profitability | ||
| Gross margin | 23.8% | 35.1% (better) |
| Operating margin | 4.3% | – |
| Net margin | 3.8% (better) | 0.79% |
| FCF margin | 22.7% (better) | 10.0% |
| Return on equity | 2.2% (better) | 0.30% |
| Return on invested capital | 1.1% | – |
| Financial health | ||
| Debt / equity | 0.18 (better) | 0.23 |
| Net debt / EBITDA | 0.27 (better) | 1.52 |
| Current ratio | 2.09 | 2.43 (better) |
| Altman Z-score | 2.24 (better) | 0.46 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 1.8% (better) | 1.7% |
| Payout ratio | 85.0% | 758% |
| Years of dividend growth | 16 (better) | 0 |
| Dividend growth, 5Y average | 1.0% | 3.6% (better) |
| Buyback yield | – | −0.71% |
| Shareholder yield | 1.8% (better) | 1.00% |
| Ownership | ||
| Held by institutions | 98.3% | 73.7% |
| Held by insiders | 0.35% | 0.95% |
| Insider net buying, 12 months | −$7.4M | −$607K (better) |
| Short interest, % of float | 10.0% | 3.8% |
Go deeper
- ALB stock overview
- ALB income statement
- ALB valuation and score
- DD stock overview
- DD income statement
- DD valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.